Biomarker Assay Services in Drug Development

Rockville, MD – Expression Pathology Inc. announced an agreement with Roche (SIX:RO, ROG; OTCQX:RHHBY) wherein Expression Pathology will provide its Liquid Tissue®- SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.

Under the terms of the agreement, Expression Pathology will support Roche oncology drug

development programs with multiplexed quantitative assays of cancer signaling pathway proteins

and their activation in FFPE tissues by mass spectrometry.

“This new approach to tissue analysis has the potential to dramatically stream-line and improve

biomarker identification in FFPE samples during clinical development,” says Dr. Miro Venturi,

Senior Biomarker & Experimental Medicine Leader at Roche. “Longer-term, we may envision

Expression Pathology’s Liquid Tissue®-SRM platform as becoming a new way of profiling tumors

at the molecular level to improve patient stratification and therefore advancing our discovery of

personalized medicines.”

“This collaboration with Roche is a key step towards developing valuable clinical assays to improve

patient treatment decisions for Roche’s innovative new targeted therapies.” says Casey Eitner,

President and CEO of Expression Pathology.

About Expression Pathology Inc.

Expression Pathology is advancing personalized medicine with assays that measure cancer signaling

networks—at the functional protein level—in FFPE tissue to individualize and improve patient

treatment decisions. Expression Pathology’s patented Liquid Tissue®-SRM technology platform

makes possible highly multiplexed protein quantitation by powerful mass spectrometry of minute

amounts of laser microdissected FFPE tissue.

Expression Pathology offers a broad menu of multiplexed SRM assays for major cancer signaling

networks to advance development of targeted therapies and improve patient stratification. The assays

include a range of drug target pathway proteins including EFGR, IGF-1R, cMET, Her3, cSRC, MEK,

and their phosphorylation states, as well as many others.